ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease

Cespiati, Annalisa; Youngson, Neil A.; Tourna, Aikaterini; Valenti, Luca*
Current Pharmaceutical Design2020DOI: 10.2174/1381612826666200122151251
12被引2阅读
引用收藏
分享

摘要

Tins narrative review will discuss the current evidence supporting the possible application of precision or personalized medicine to the management of nonalcoholic or "metabolic" fatty liver disease (NAFLD), based on recent progress in the understanding of the genetics and epigenetics of the disease. The prevalence of NAFLD, which can progress to cirrhosis and hepatocellular carcinoma, is constantly increasing worldwide. Accurate non-invasive predictors of liver disease progression, as well as of cardiovascular complications of NAFLD, are urgently needed. Evidence is now reporting that the genetic and epigenetic factors involved in NAFLD development can be used to develop risk scores for liver-related complications, which may show the possibility to implement programs for targeted screening and surveillance of complications. Moreover, genetic and epigenetic therapies. Finally, we describe opportunities for gene-targeted therapeutic approaches in NAFLD, where the factors identifying specific sub-phenotypes of NAFLD can predict the individual response to pharmacological genetic variants represent therapeutic targets for precision therapy approaches.

学科与关键词

关键词
Biomarkernonalcoholic fatty liver diseasenonalcoholic steatohepatitisprecision medicinecirrhosishepatocellular
相关
加载中…
  • Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
    Che, Wensheng; Zhao, Ming; Li, Xiaoqing; Li, Chunlong*; Cho, William C.*; Yu, Shan*Frontiers in Endocrinology, 2022, 13: 1002916.被引 2
  • The blind men 'see' the elephant-the many faces of fatty liver disease
    Madhusudana Girija Sanal*World Journal of Gastroenterology, 2008, (06): 831-844.
  • Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
    Pirola, Carlos J.; Sookoian, Silvia*WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24(15): 1601-1615.被引 51
查看全部 →

发表信息

论文状态
公开发表
期刊
Current Pharmaceutical Design
发表日期
2020
卷期
第 26 卷, 第 10 期
页码
998-1009
DOI
10.2174/1381612826666200122151251
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
4区
成果收录
SCIE
资助标注
MyFirst Grant AIRC [16888]; Ricerca Finalizzata Ministero della Salute [RF-2016-02364358]; Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Fondazione Sviluppo Ca' Granda [PR-0361]; European Union (EU) Programme Horizon 2020 [777377]

作者

  • C

    Cespiati, Annalisa (第一作者)

  • Y

    Youngson, Neil A.

查看全部 4 位作者收起作者
  • T

    Tourna, Aikaterini

  • V

    Valenti, Luca (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417